Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
SAN DIEGO, Nov. 03, 2016 -- Poseida Therapeutics Inc. (“Poseida”), a San Diego-based company translating best-in-class gene editing technologies into lifesaving therapeutics, today announced that three abstracts detailing preclinical data on P-BCMA-101, the company’s BCMA-specific CAR-T drug candidate, have been selected for presentation at the American Society of Hematology (ASH) Annual Meeting. The studies explore utility and performance of Poseida’s proprietary CAR-T modifications using its piggyBac™ non-viral gene delivery system and Centyrin binding scaffold. Data will be presented at the 2016 ASH Annual Meeting in San Diego on December 3rd and 5th. Abstracts are currently available online at http://www.hematology.org/Annual-Meeting/.
The following abstracts will be presented:
Presentation Title: A Novel BCMA-Specific, Centyrin-Based CAR-T Product for the Treatment of Multiple Myeloma
Abstract Number: 2127
Date and Time: 5:30 p.m. - 7:30 p.m., Saturday, December 3, 2016
Location: San Diego Convention Center, Hall GH
Presentation Title: piggyBac™-Produced CAR-T Cells Exhibit Stem-Cell Memory Phenotype
Abstract Number: 2167
Date and Time: 5:30 p.m. - 7:30 p.m., Saturday, December 3, 2016
Location: San Diego Convention Center, Hall GH
Presentation Title: Development of Novel Non-Immunoglobulin Centyrin-Based CARs (CARTyrins) Targeting Human BCMA
Abstract Number: 4557
Date and Time: 6:00 p.m. - 8:00 p.m., Monday, December 5, 2016
Location: San Diego Convention Center, Hall GH
About Poseida Therapeutics, Inc.
Poseida Therapeutics is translating best-in-class gene editing technologies into lifesaving treatments. The company is developing CAR T-cell immunotherapies for multiple myeloma and other cancer types, as well as gene therapies for orphan diseases. Poseida is also partnered with Janssen Biotech to develop allogeneic CAR T-cell therapies using Poseida’s gene editing platform. Poseida has assembled a suite of industry-leading gene editing technologies, including the piggyBac™ DNA Modification System, XTN™ TALEN and NextGEN™ CRISPR site-specific nucleases, and Footprint-Free™ Gene Editing (FFGE). For more information, visit www.poseida.com.
Corporate Communications Contact: Jason Spark Canale Communications 619-849-6005 [email protected]
